New hope for rare tumors: drug may slow cancer growth
NCT ID NCT03946527
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called lanreotide in 10 people with advanced or metastatic paraganglioma or pheochromocytoma, rare tumors that release hormones. The goal is to see if lanreotide can slow tumor growth compared to before treatment. Participants receive injections every 4 weeks, and doctors monitor tumor size and hormone levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- Can a radioated molecule shrink untreatable neuroblastoma?
- New drug aims to shrink rare adrenal tumors
- Could a smartphone replace clinic visits for rare tumor survivors?
- Could a cancer drug quiet overactive adrenal hormones? a new study investigates.